We are live on ! Find out more
LAB icon

Standard BioTools
LAB

86 hedge funds and large institutions have $70.2M invested in Standard BioTools in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.91% less ownership

Funds ownership: 64.72% → 56.8% (-7.9%)

21% less funds holding

Funds holding: 109 → 86 (-23)

29% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 28

48% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 40

61% less capital invested

Capital invested by funds: $179M → $70.2M (-$109M)

69% less call options, than puts

Call options by funds: $109K | Put options by funds: $352K

Holders
86
Holders Change
-23
Holders Change %
-21.1%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
20
Reduced
28
Closed
40
Calls
$109K
Puts
$352K
Net Calls
-$243K
Net Calls Change
+$420K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$4.92M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.81M
3
Millennium Management
Millennium Management
New York
+$1.63M
4
E
Ergoteles
New York
+$862K
5
Citadel Advisors
Citadel Advisors
Florida
+$515K

Top Sellers

1
BlackRock
BlackRock
New York
-$10.3M
2
N
Nuveen
North Carolina
-$5.87M
3
PHS
PFM Health Sciences
California
-$3.52M
4
State Street
State Street
Massachusetts
-$2.98M
5
UBS Group
UBS Group
Switzerland
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Indaba Capital Management
California
$11.9M – – –
Primecap Management
2
Primecap Management
California
$7.93M -$172K -69,730 -1%
Neuberger Berman Group
3
Neuberger Berman Group
New York
$6.35M +$37.3K +15,072 +0.4%
NIM
4
Needham Investment Management
New York
$6.2M +$236K +95,565 +3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.69M -$889K -359,278 -9%
Morgan Stanley
6
Morgan Stanley
New York
$4.96M +$349K +141,274 +5%
BFM
7
Boothbay Fund Management
New York
$3.71M +$46.6K +18,844 +0.8%
BlackRock
8
BlackRock
New York
$3.23M -$10.3M -4,148,506 -67%
RCM
9
RA Capital Management
Massachusetts
$3.18M +$4.92M +1,987,589 New
Millennium Management
10
Millennium Management
New York
$2.17M +$1.63M +659,831 +95%
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$1.82M +$2.81M +1,137,361 New
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$1.53M -$31.5K -12,723 -1%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$1.42M +$146K +59,007 +7%
PVI
14
Pura Vida Investments
New York
$1.36M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.13M -$1.56M -632,190 -47%
E
16
Ergoteles
New York
$557K +$862K +348,400 New
HighTower Advisors
17
HighTower Advisors
Illinois
$538K +$360K +145,683 +77%
State Street
18
State Street
Massachusetts
$536K -$2.98M -1,203,269 -78%
Citadel Advisors
19
Citadel Advisors
Florida
$421K +$515K +208,289 +379%
JCP
20
Jennifer C. Price
$392K +$606K +245,000 New
Goldman Sachs
21
Goldman Sachs
New York
$385K +$200K +80,849 +51%
Renaissance Technologies
22
Renaissance Technologies
New York
$371K +$283K +114,400 +97%
SAM
23
Silverback Asset Management
North Carolina
$320K – – –
FAM
24
Fred Alger Management
New York
$313K -$507K -204,798 -51%
Tudor Investment Corp
25
Tudor Investment Corp
Connecticut
$308K +$217K +87,598 +83%
1
2 3 4 5

LAB Hedge Fund Activity: Q2 2022 in Review

86 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2022, worth a combined $70.2M — down 61% from $179M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of LAB and 21 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 20 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $4.92M. The largest seller was BlackRock, cutting an estimated $10.3M.

  • 86 institutional investors held Standard BioTools (LAB) as of Q2 2022, down from 109 in Q1 2022.
  • Funds reported $70.2M of Standard BioTools stock for Q2 2022, down 61% quarter-over-quarter.
  • 21 funds opened new Standard BioTools positions in Q2 2022 and 40 closed out, a net change of -19 holders.
  • The largest Standard BioTools buyer in Q2 2022 was RA Capital Management, an estimated $4.92M added.
  • The largest Standard BioTools seller in Q2 2022 was BlackRock, an estimated $10.3M sold.

Based on aggregated 13F filings for Q2 2022.